An interventional study of Plant-based intensive lifestyle intervention and Standard of Care in Diabetes Mellitus, sponsored by University of Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by University of Toronto · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Diabetes Mellitus by University of Toronto — 2 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus · University of Toronto.
Among the 41 studies in Diabetes Mellitus by University of Toronto, this one is the 4th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2025, is one of 20 with no phase, and was the 40th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 41 studies in Diabetes Mellitus by University of Toronto are open now, in 1 country. Recruiting first, the newest first:
University of Toronto · Sites in Canada
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 1 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 32 across the 24 interventional studies, 1 across the 14 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Toronto is the lead sponsor of 405 studies on the registry; 51 are open to participants now.
1 of the studies in Diabetes Mellitus by University of Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486050University of TorontoThe Impact of Social Worker Referrals on Diabetes and Loneliness | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Diabetes Mellitus by University of Toronto, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if a plant-based intensive lifestyle intervention can achieve remission of diabetes. It will also learn if a plant-based intensive lifestyle intervention can achieve weight loss ≥15% of initial body weight.
The main questions it aims to answer are:
Researchers will compare the plant-based intensive lifestyle intervention to the current standard of care.
Participants will be randomly placed into one of two groups:
Participants in the standard of care will:
Participants in the plant-based intensive lifestyle intervention will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo a plant-based intensive lifestyle intervention targeting weight loss with the goal of achieving diabetes remission. All antihyperglycemic and/or antihypertensive medications will be stopped at the first visit as a safety measure. The interventions will be delivered at clinic visits at 2-4week intervals over the 52-weeks.
Behavioral: Plant-based intensive lifestyle intervention
Participants will continue to receive usual diabetes and obesity management with their health care provider(s) as per current Canadian clinical practice guidelines. Participants will attend clinic visits on 5 occasions over the 52-weeks.
Other: Standard of Care
The plant-based intensive lifestyle intervention has 2 phases. The first 12-weeks is a weight loss phase consisting of a plant-based, high-plant protein energy restricted total diet replacement (TDR), psyllium-based fibre and complete multivitamin supplements, and vegetable bouillon, with the option of continuing with this phase up to week 20. The second phase is weight-loss maintenance beginning with an 8-week (weeks 12-20) stepped food reintroduction phase with partial meal replacement, progressing towards the 32-week (weeks 20-52) full food introduction phase. These phases focus on introducing a plant-based, high-plant protein, energy balanced, weight loss maintenance diet, which will be supported by a digital program. At weeks 12-28, a 16-week in-person structured exercise training program will be delivered followed by 2-weekly motivational phone calls until the 52-weeks. A 19-session, group-based, structured behavioural support program will be delivered throughout the study.
Participants will continue to receive usual diabetes and obesity management as per current Canadian clinical practice guidelines. The management will continue to be delivered to participants through their family doctor, nurse practitioner, or diabetes care team with standard frequency of contact. Participants will attend clinic visits on 5 occasions (weeks 0, 12, 28, 40 and 52) and will receive motivational phone calls between visits to provide reminders regarding follow-up with their diabetes care providers.
Proportion achieving diabetes remission
Proportion achieving diabetes remission, defined as an HbA1C \<6.5% for ≥3 months free of antihyperglycemic medications at 52 weeks.
Time frame: From enrollment to the end of treatment at 52 weeks.
Key secondary: Proportion achieving ≥15% weight loss
Proportion achieving ≥15% weight loss from baseline at 52 weeks.
Time frame: From enrollment to the end of treatment at 52 weeks.
Proportion achieving ≥10% and ≥5% weight loss from baseline change
Proportion achieving ≥10% and ≥5% weight loss from baseline at 52 weeks
Time frame: From enrollment to the end of treatment at 52 weeks
Changes in measures of body composition
Changes in body weight
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in measures of body composition
Changes in body mass index
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in measures of body composition
Changes in waist circumference
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in measures of body composition
Changes in body fat
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in measures of body composition
Changes in lean body mass
Time frame: From enrollment to the end of treatment at 52 weeks.
Proportion experiencing relapse
Proportion experiencing relapse, defined as having achieved remission at any time during the trial but having an HbA1c ≥6.5% at 52 weeks.
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in functional tests
Changes in sit-stand chair
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in functional tests
Changes in grip test
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in glycemic control
Changes in HbA1c
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in glycemic control
Changes in fasting plasma glucose
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in blood lipids
Changes in LDL-cholesterol, non-HDL cholesterol, HDL-cholesterol, total cholesterol and triglycerides.
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in blood pressure
Changes in systolic and diastolic blood pressure.
Time frame: From enrollment to the end of treatment at 52 weeks.
Changes in inflammation
Changes in c-reactive protein (CRP)
Time frame: From enrollment to the end of treatment at 52 weeks
Plan to share: Yes — All outcomes listed will be shared in an anonymous/de-identified format.
Supporting information: Study protocol
Time frame: IPD and supporting information will be available after the anticipated study completion date from January 2030 and will remain for 30 years until January 2060.
Access criteria: IPD data will be accessible though the University of Toronto Dataverse (https://borealisdata.ca/dataverse/toronto). The metadata record of our dataset will be public, however access to the data will be restricted. Users will need to request access using the contact information provided in order to view and download our restricted files.
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Dec 2028, 39 months later.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 39 months is above that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.